Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    LONG-TERM SAFETY AND EFFICACY STUDY OF IGNG, A NEW LIQUID PREPARATION OF HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE, ADMINISTERED IN CURRENT PRACTICE TO PRIMARY IMMUNODEFICIENT PATIENTS

    Summary
    EudraCT number
    2007-001410-17
    Trial protocol
    FR  
    Global end of trial date
    28 Jan 2011

    Results information
    Results version number
    v1(current)
    This version publication date
    30 Jun 2016
    First version publication date
    04 Oct 2014
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    IGNG-0629
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    LFB Biotechnologies
    Sponsor organisation address
    3 Avenue des tropiques - BP 40305, COURTABOEUF, France, 91958
    Public contact
    Anne HUFSCHMITT, LFB Biotechnologies, 33 169827014,
    Scientific contact
    Anne HUFSCHMITT, LFB Biotechnologies, 33 169827014,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    20 Jun 2011
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    28 Jan 2011
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Jan 2011
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objective of the study is to assess the clinical and biological safety of IGNG by considering adverse events in patients treated for their primary immunodeficiency as per current practice over at least a 2-year-period.
    Protection of trial subjects
    Patients will be followed in this study in conditions corresponding to the current practice of the investigational centres, which are familiar in treating patients with human normal immunoglobulins for PID. Patients will benefit from IGNG administered in the same conditions and by the same medical staff as in current practice. Consequently, the study does not contain additional risk.
    Background therapy
    Not applicable
    Evidence for comparator
    No comparator.
    Actual start date of recruitment
    13 Jun 2007
    Long term follow-up planned
    Yes
    Long term follow-up rationale
    Safety, Efficacy
    Long term follow-up duration
    31 Months
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    France: 23
    Worldwide total number of subjects
    23
    EEA total number of subjects
    23
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    6
    Adults (18-64 years)
    17
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Between 13 June 2007 and 17 June 2008, 23 patients (17 adults and 6 adolescents) were included in 10 French investigational sites.

    Pre-assignment
    Screening details
    Patients who met all the inclusion criteria and none of the exclusion criteria were included in this clinical trial after their informed consent was signed. In females of childbearing potential, a negative pregnancy test had to be obtained before inclusion.

    Period 1
    Period 1 title
    Inclusion visit or visit 0
    Is this the baseline period?
    Yes
    Allocation method
    Non-randomised - controlled
    Blinding used
    Not blinded

    Arms
    Arm title
    IGNG (ClairYg)
    Arm description
    All patients
    Arm type
    Experimental

    Investigational medicinal product name
    ClairYg
    Investigational medicinal product code
    IGNG
    Other name
    Pharmaceutical forms
    Solution for injection/infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    The treatment dose and schedule were set by investigators, based on their common clinical practice, but between 0.2 and 0.8 g/kg every 3 or 4 weeks.

    Number of subjects in period 1
    IGNG (ClairYg)
    Started
    23
    Completed
    23
    Period 2
    Period 2 title
    Treatment phase
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    IGNG (Clairyg)
    Arm description
    All the patients received the experimental product.
    Arm type
    Experimental

    Investigational medicinal product name
    Clairyg
    Investigational medicinal product code
    IGNG
    Other name
    Pharmaceutical forms
    Solution for injection/infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    The doses recommended in the protocol could vary depending on the patient and were between 0.2 and 0.8 g/kg administered every 3 or 4 weeks.

    Number of subjects in period 2
    IGNG (Clairyg)
    Started
    23
    Completed
    16
    Not completed
    7
         Consent withdrawn by subject
    5
         Adverse event, non-fatal
    2
    Period 3
    Period 3 title
    End of study visit
    Is this the baseline period?
    No
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    IGNG (ClairYg)
    Arm description
    All patients in the same arm
    Arm type
    Experimental

    Investigational medicinal product name
    ClairYg
    Investigational medicinal product code
    IGNG
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Intravenous use
    Dosage and administration details
    The doses recommended in the protocol could vary depending on the patient and were between 0.2 and 0.8 g/kg administered every 3 or 4 weeks.

    Number of subjects in period 3
    IGNG (ClairYg)
    Started
    16
    Completed
    16

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Inclusion visit or visit 0
    Reporting group description
    -

    Reporting group values
    Inclusion visit or visit 0 Total
    Number of subjects
    23 23
    Age categorical
    2 different subject categories: adolescents and adults
    Units: Subjects
        Adolescents (12-17 years)
    6 6
        Adults (18-64 years)
    17 17
    Age continuous
    We do not understand what is required here.
    Units: years
        arithmetic mean (standard deviation)
    34.4 ( 16.2 ) -
    Gender categorical
    Units: Subjects
        Female
    11 11
        Male
    12 12
    Subject analysis sets

    Subject analysis set title
    Total Treated Set (TTS)
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Tthe Total Treated Set (TTS) includes all patients who received at least one infusion of the investigational drug. All of the analyses were performed on this population.

    Subject analysis sets values
    Total Treated Set (TTS)
    Number of subjects
    23
    Age categorical
    2 different subject categories: adolescents and adults
    Units: Subjects
        Adolescents (12-17 years)
    6
        Adults (18-64 years)
    17
    Age continuous
    We do not understand what is required here.
    Units: years
        arithmetic mean (standard deviation)
    34.4 ( 16.2 )
    Gender categorical
    Units: Subjects
        Female
    11
        Male
    12

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    IGNG (ClairYg)
    Reporting group description
    All patients
    Reporting group title
    IGNG (Clairyg)
    Reporting group description
    All the patients received the experimental product.
    Reporting group title
    IGNG (ClairYg)
    Reporting group description
    All patients in the same arm

    Subject analysis set title
    Total Treated Set (TTS)
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Tthe Total Treated Set (TTS) includes all patients who received at least one infusion of the investigational drug. All of the analyses were performed on this population.

    Primary: number of adverse events

    Close Top of page
    End point title
    number of adverse events [1]
    End point description
    All adverse events, disregarding if they are related to study drug or not.
    End point type
    Primary
    End point timeframe
    troughout the study
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: descriptive analysis
    End point values
    IGNG (Clairyg) Total Treated Set (TTS)
    Number of subjects analysed
    23
    23
    Units: number
    333
    333
    No statistical analyses for this end point

    Secondary: Annual rate of serious bacterial infection

    Close Top of page
    End point title
    Annual rate of serious bacterial infection
    End point description
    End point type
    Secondary
    End point timeframe
    throughout the study
    End point values
    IGNG (Clairyg) Total Treated Set (TTS)
    Number of subjects analysed
    23 [2]
    23
    Units: annual rate
        arithmetic mean (confidence interval 98%)
    0.05 (0.01 to 0.17)
    0.05 (0.01 to 0.17)
    Notes
    [2] - Annual rate is calculated using the exact Poisson test
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    overall the study
    Adverse event reporting additional description
    For non-serious adverse events only most common adverse events (occurence > 5) are reporting here.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    9.1
    Reporting groups
    Reporting group title
    All patients
    Reporting group description
    -

    Serious adverse events
    All patients
    Total subjects affected by serious adverse events
         subjects affected / exposed
    11 / 23 (47.83%)
         number of deaths (all causes)
    1
         number of deaths resulting from adverse events
    0
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    probable lymph node infection with atypical mycobacterium
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Immune system disorders
    Splenomegaly
    Additional description: aggravated
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Anaphylactic shock
    Additional description: Related (Probable)
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Ear and labyrinth disorders
    Superinfection of the eardrum
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Eye disorders
    Cataract
    Additional description: aggravation of cataract
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Inguinal hernia
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Abdominal pain
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastroenteritis
    Additional description: Severe
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Reproductive system and breast disorders
    Mastoiditis
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Atelectasis
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Chronic respiratory disease
    Additional description: chronic respiratory insufficiency
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory distress
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pulmonary hypertension
         subjects affected / exposed
    2 / 23 (8.70%)
         occurrences causally related to treatment / all
    1 / 2
         deaths causally related to treatment / all
    0 / 1
    Asthma
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia pneumococcal
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Superinfection
    Additional description: bronchial superinfection
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Bronchiectasis
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Cirrhosis
    Additional description: Decompensated cirrhosis
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 1
    Liver disorder
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatitis chronic active
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Pyelonephritis
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    kidney failure
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal failure chronic
    Additional description: Related (Dubious)
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal failure acute
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Depression
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Musculoskeletal and connective tissue disorders
    retractile capsulitis of the shoulder
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Sinusitis
    Additional description: acute
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    left purulent lynphadenitis
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Implant site infection
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Superinfection of the molluscum
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0.45%
    Non-serious adverse events
    All patients
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    23 / 23 (100.00%)
    Vascular disorders
    Epistaxis
         subjects affected / exposed
    5 / 23 (21.74%)
         occurrences all number
    13
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    6 / 23 (26.09%)
         occurrences all number
    12
    Hyperthermia
         subjects affected / exposed
    4 / 23 (17.39%)
         occurrences all number
    5
    Pain at the administration site
         subjects affected / exposed
    2 / 23 (8.70%)
         occurrences all number
    8
    Pain
         subjects affected / exposed
    3 / 23 (13.04%)
         occurrences all number
    16
    Headache
         subjects affected / exposed
    3 / 23 (13.04%)
         occurrences all number
    10
    Pruritus
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences all number
    7
    Gastrointestinal disorders
    Abdominal pain
         subjects affected / exposed
    5 / 23 (21.74%)
         occurrences all number
    8
    uper abdominal pain
         subjects affected / exposed
    5 / 23 (21.74%)
         occurrences all number
    5
    Diarrhoea
    Additional description: non infectious
         subjects affected / exposed
    5 / 23 (21.74%)
         occurrences all number
    9
    Gastrointestinal disorder
         subjects affected / exposed
    3 / 23 (13.04%)
         occurrences all number
    5
    Respiratory, thoracic and mediastinal disorders
    Asthma
         subjects affected / exposed
    1 / 23 (4.35%)
         occurrences all number
    7
    Musculoskeletal and connective tissue disorders
    Joint pain
         subjects affected / exposed
    4 / 23 (17.39%)
         occurrences all number
    15
    Back pain
         subjects affected / exposed
    7 / 23 (30.43%)
         occurrences all number
    10
    Pain in the extremities
         subjects affected / exposed
    5 / 23 (21.74%)
         occurrences all number
    13

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    09 Oct 2007
    The Sponsor's name is changed from LFB SA to LFB Biotechnologies.
    08 Feb 2008
    This amendment has been mainly put forward in order to open paediatric Investigational centres. It also includes an additional adult Investigational centre to increase the number of adult patients. Consequently, the recruitment period, which ought to end on 31st of December 2007, will be extended to 30th June 2008. Therefore, the recruitment period will last 1 year instead of 6 months initially scheduled.
    12 Feb 2009
    In the initial protocol, the study duration for each patient was 2 years. This amendment extends the study until the product is marketed. An additional consent form will be signed by the patients if they want to continue the study until the product is marketed. Patient's assurance will be extended accordingly.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 23:39:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA